712 related articles for article (PubMed ID: 29699580)
21. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
Wittrant Y; Théoleyre S; Chipoy C; Padrines M; Blanchard F; Heymann D; Rédini F
Biochim Biophys Acta; 2004 Sep; 1704(2):49-57. PubMed ID: 15363860
[TBL] [Abstract][Full Text] [Related]
22. Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection.
Miller RE; Branstetter D; Armstrong A; Kennedy B; Jones J; Cowan L; Bussiere J; Dougall WC
J Immunol; 2007 Jul; 179(1):266-74. PubMed ID: 17579046
[TBL] [Abstract][Full Text] [Related]
23. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
24. Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond.
Deligiorgi MV; Panayiotidis MI; Griniatsos J; Trafalis DT
Clin Exp Metastasis; 2020 Feb; 37(1):13-30. PubMed ID: 31578655
[TBL] [Abstract][Full Text] [Related]
25. Is the normal content of sulfhydryl groups attributable to sparing from dystrophic pathology in dystrophin-deficient muscles?
Niebrój-Dobosz I; Fidziańska A; Glinka Z; Hausmanowa-Petrusewicz I
Folia Neuropathol; 2002; 40(3):143-50. PubMed ID: 12572920
[TBL] [Abstract][Full Text] [Related]
26. Nutraceutical and pharmaceutical cocktails did not improve muscle function or reduce histological damage in D2-mdx mice.
Spaulding HR; Quindry T; Hammer K; Quindry JC; Selsby JT
J Appl Physiol (1985); 2019 Oct; 127(4):1058-1066. PubMed ID: 31295065
[TBL] [Abstract][Full Text] [Related]
27. Effect of injecting primary myoblasts versus putative muscle-derived stem cells on mass and force generation in mdx mice.
Mueller GM; O'Day T; Watchko JF; Ontell M
Hum Gene Ther; 2002 Jun; 13(9):1081-90. PubMed ID: 12067441
[TBL] [Abstract][Full Text] [Related]
28. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
[TBL] [Abstract][Full Text] [Related]
29. Isometric resistance training increases strength and alters histopathology of dystrophin-deficient mouse skeletal muscle.
Lindsay A; Larson AA; Verma M; Ervasti JM; Lowe DA
J Appl Physiol (1985); 2019 Feb; 126(2):363-375. PubMed ID: 30571283
[TBL] [Abstract][Full Text] [Related]
30. OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice.
Shimamura M; Nakagami H; Osako MK; Kurinami H; Koriyama H; Zhengda P; Tomioka H; Tenma A; Wakayama K; Morishita R
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8191-6. PubMed ID: 24847069
[TBL] [Abstract][Full Text] [Related]
31. Muscle RANK is a key regulator of Ca2+ storage, SERCA activity, and function of fast-twitch skeletal muscles.
Dufresne SS; Dumont NA; Boulanger-Piette A; Fajardo VA; Gamu D; Kake-Guena SA; David RO; Bouchard P; Lavergne É; Penninger JM; Pape PC; Tupling AR; Frenette J
Am J Physiol Cell Physiol; 2016 Apr; 310(8):C663-72. PubMed ID: 26825123
[TBL] [Abstract][Full Text] [Related]
32. Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice.
Wada E; Tanihata J; Iwamura A; Takeda S; Hayashi YK; Matsuda R
Skelet Muscle; 2017 Oct; 7(1):23. PubMed ID: 29078808
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity.
Cox GA; Cole NM; Matsumura K; Phelps SF; Hauschka SD; Campbell KP; Faulkner JA; Chamberlain JS
Nature; 1993 Aug; 364(6439):725-9. PubMed ID: 8355788
[TBL] [Abstract][Full Text] [Related]
34. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
35. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
36. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
Armada L; Marotta Pdos S; Pires FR; Siqueira JF
J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
[TBL] [Abstract][Full Text] [Related]
37. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
38. Lipogenesis mitigates dysregulated sarcoplasmic reticulum calcium uptake in muscular dystrophy.
Paran CW; Zou K; Ferrara PJ; Song H; Turk J; Funai K
Biochim Biophys Acta; 2015 Dec; 1851(12):1530-8. PubMed ID: 26361872
[TBL] [Abstract][Full Text] [Related]
39. Truncated dystrophin ameliorates the dystrophic phenotype of mdx mice by reducing sarcolipin-mediated SERCA inhibition.
Tanihata J; Nagata T; Ito N; Saito T; Nakamura A; Minamisawa S; Aoki Y; Ruegg UT; Takeda S
Biochem Biophys Res Commun; 2018 Oct; 505(1):51-59. PubMed ID: 30236982
[TBL] [Abstract][Full Text] [Related]
40. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.
Vitovski S; Phillips JS; Sayers J; Croucher PI
J Biol Chem; 2007 Oct; 282(43):31601-9. PubMed ID: 17702740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
